Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

3 Months Ended

Oct. 31, 2023

The following financial information represents the operating results of the reportable segments of the Company:

	Products			Corporate & Other			Consolidated
Revenues	$	7,806			—		$	7,806

Operating costs and expenses:
Cost of revenues		4,351			—			4,351
Research and development		838		$	11			849
Selling, general and administrative		3,104			3,903			7,007
Legal and related expenses		30			1,045			1,075
Total operating costs and expenses		8,323			4,959			13,282

Operating loss		(517	)		(4,959	)		(5,476	)

Other income (expense)
Interest		34			943			977
Change in fair value of convertible debentures		—			(328	)		(328	)
Other		2			156			158
Foreign exchange loss		(1,006	)		—			(1,006	)
Loss before taxes	$	(1,487	)	$	(4,188	)	$	(5,675	)

Depreciation and amortization included above	$	166		$	104		$	270

Share-based compensation included above:
Selling, general and administrative		22			1,047			1,069
Cost of sales		6			—			6
Total	$	28		$	1,047		$	1,075

Capital expenditures	$	248		$	6		$	254

	Products			Corporate & Other			Consolidated
Revenues	$	7,103			—		$	7,103

Operating costs and expenses:
Cost of revenues		4,589			—			4,589
Research and development		690		$	9			699
Selling, general and administrative		2,885			2,552			5,437
Legal and related expenses		25			982			1,007
Total operating costs and expenses		8,189			3,543			11,732

Operating loss		(1,086	)		(3,543	)		(4,629	)

Other income (expense)
Interest		25			47			72
Other		2			(2	)		—
Foreign exchange loss		(797	)		—			(797	)
Loss before taxes	$	(1,856	)	$	(3,498	)	$	(5,354	)

Depreciation and amortization included above	$	165		$	83		$	248

Share-based compensation included above:
Selling, general and administrative		20			340			360
Cost of sales		6			—			6
Total	$	26		$	340		$	366

Capital expenditures	$	306		$	183		$	489